Edra designs advanced solutions that reshape the value chain and contribute to tangibly building the future of the Healthcare system. Edra designs new processes, new platforms, new systems to improve the knowledge and the decisions of patients, clinics, pharmacists, decision makers: levers that can drive the evolution of the system, guaranteeing better dialogue, the prompt availability of essential information and effective processes.

It provides custom solutions and services thanks to a dedicated team of professionals that operate in the following areas: publications & advisory boards, digital solutions, residential, on-the-job and online training, communication & pr.

For further information visit www.edraspa.it and to explore the scientific publications published by Edra visit https://www.edraspa.it/competenze/pubblicazioni/

Please, take into consideration that Edra webiste is in Italian language.


Sharing the same ethical value, Edra S.p.A publishes The European Annals of Allergy and Clinical Immunology on behalf of the “Associazione Allergologi Immunologi Italiani Territoriali e Ospedalieri” (Association of Italian Hospital Allergists and Immunologists – AAIITO) and the “Sociedade Portuguesa de Alergologia e Imunologia Clinica” (Portuguese Society of Allergology and Clinical Immunology – SPAIC).

Edra SpA applies rigorous Ethical standards to guarantee high-quality scientific publications to respect the willingness of AAIITO and SPAIC.

The submitted manuscripts must comply with the policies of The European Annals of Allergy and Clinical Immunology. In case of need, the guidelines based on the Committee on Publication Ethics (COPE) on good publication practice can be consulted.

Edra supports the COPE Core Practices, along with AAIITO and SPAIC, specifically in case of  Complaints and Appeals, discussed below. For Authorship criteria or Clinical trial registration or Information about Conflict of interests, the Publisher endorses the recommendations of the International Committee of Medical Journal Editors (http://www.icmje.org/).


Edra entrusts to Editorial Manager® by Aries Systems Corporation to the submission of the manuscripts, where one of the authors listed – usually the Corresponding author – is called to upload the manuscript in behalf of all the authors. The submitted manuscript must be original and must not have been published nor submitted for publication elsewhere.

When a new submission is received, the publisher’s office conducts an initial check of format and completeness of authors to assess if the authors followed the Instructions for authors. In case of discrepancies, the Editorial Office send back the manuscript with detailed information about the errors and the required modifications.

Involved parts

All submitted manuscripts are confidential documents. No information will be shared without the written permission of the author(s).

During the revision process, the following people may access to manuscripts:

  • Editors;
  • Members of Editorial Office;
  • Reviewers;
  • Authors.

In case of serious misconduct research, the Journal reserves the right to involve third parties.

Article withdrawal

Edra admits articles withdrawal upon request from the authors, in case manuscript has not received a final decision yet.

In case of acceptance and authors’ withdrawal willingness:

  • If a doi has not already been associated to the article, the article will be archived without publication.
  • If a doi has been already associated to the article due to the publication as ahead of print, the request of withdrawal will be rejected, and a retraction note will be attached to the article.
  • If the article is ready to be published in a specific volume ad issue, the request of withdrawal will be rejected, and the article published with a retraction note.


Authors are called to sign a conflict of interest form provided by Edra during the proofreading phase. All the authors should sign: in case of difficulties in gathering all the signatures and absence of conflict of interests, only the corresponding authors can sign it in behalf of all the authors.

A conflict of interest may exist when an author or the author’s institution has a financial or other relationship with other people or organizations within three (3) years of beginning the work submitted that could inappropriately influence (bias) their work. Financial relationships are easily identifiable, but conflicts can also occur because of personal relationships, academic competition, or intellectual rivalry. A conflict can be actual or potential and full disclosure to the Journal is the safest course. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.

The Conflict of interest can be:

  • Employment
  • Research funding (including funds received or pending for research in which one of more authors were the principal investigator, collaborator, or consultant)
  • Other Research Support (including receipt of drugs, supplies, equipment, or other in-kind support)
  • Honoraria (including fees received for speaking during symposia and other meetings or occasions)
  • Expert Witness (serving as an expert witness, consultant or otherwise providing a deposition, testimony, or other information, analysis or document for a lawsuit, government agency proceeding, grand jury, or other legal proceeding, even if the case did not go to trial)
  • Ownership Interest (stocks or stock options; partnership, membership, any rights in any patent or other intellectual property)
  • Other
  • None


Manuscripts that report the results of research conducted on human subjects should include a declaration that the study protocol was approved by the competent Ethics Committee, that the study was conducted in accordance with the ethical standards established in the Declaration of Helsinki of 1946, and that informed consent was obtained from all participants before enrolment in the study.

If experiments have been conducted on animals, the study must have been conducted in accordance with the International Animal Research Regulations (Institute of Medicine (US); National Research Council (US). International Animal Research Regulations: Impact on Neuroscience Research: Workshop Summary. Washington (DC): National Academies Press (US), and such adherence must be explicitly stated in the manuscript.

If a paper has been submitted from a country where there is no ethics committee, institutional review board, or similar review and approval, authors should explain how the study adhered to the World Medical Association Declaration of Helsinki: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/


All material published by Edra is protected by “Associazione Allergologi Immunologi Italiani Territoriali e Ospedalieri – AAIITO copyright, including the right to provide the Article in electronic and online forms and systems. With respect to supplemental data that the authors make accessible through a link in the Article, they hereby grant a non-exclusive license for such linking.

The authors retain or are hereby granted the Rights:

  • in patents, trademarks or other intellectual property rights;
  • to use the Preprint or Accepted Author Manuscript for:
    • Personal Use: use by an author in the author’s classroom teaching ‒ including distribution of copies, paper or electronic ‒, distribution of copies to research colleagues for their personal use, use in a subsequent compilation of the author’s works, inclusion in a thesis or dissertation, preparation of other derivative works such as extending the article to book-length form, or otherwise using or re-using portions or excerpts in other works ‒ with full acknowledgment of the original publication of the article;
    • Internal Institutional Use: use by the author’s institution for classroom teaching at the institution including distribution of copies, paper or electronic, and use in course packs and courseware programs. For authors employed by companies, the use by that company for internal training purposes;
    • Scholarly Purposes: voluntary posting of Articles or Preprints by an author on open Web sites operated by the author or the author’s institution for scholarly purposes, as determined by the author, or on preprint servers, but not for Commercial Use or Systematic Distribution. The author should include the appropriate bibliographic citation when posting.
  • the right to use the Published Journal Articles for personal use and internal institutional use.

In each case Commercial Use or Systematic Distribution are excluded.

Commercial Use means the use or posting of articles for commercial gain or to substitute for the services provided directly by the journal including:

  • the posting by companies of their employee-authored works for use by customers of such companies (e.g. pharmaceutical companies and physician-prescribers);
  • commercial exploitation such as directly associating advertising with such posting or the charging of fees for document delivery or access.

Systematic distribution means Policies or other mechanisms designed to aggregate and openly disseminate manuscripts or articles, or to substitute for journal-provided services, including:

  • the systematic distribution to others via e-mail lists or list servers (to parties other than known colleagues), whether for a fee or for free;
  • the posting of links to sponsored articles by commercial third parties including pharmaceutical companies;
  • institutional, funding body or government manuscript posting policies or mandates that aim to aggregate and openly distribute the accepted, peer reviewed manuscripts or published journal articles authored by its researchers or funded researchers;
  • subject repositories that aim to aggregate and openly distribute accepted peer-reviewed manuscripts or published journal articles authored by researchers in specific subject areas.

Each individual interested in reproducing tables, figures or intended to cite entirely or a part of the published articles contacts editorialoffice@eur-ann-allergy-clin-immunol.com to request the permission to reproduce our content. Usually, the Editorial Office releases the permission if an appropriate citation to the article and Journal is guaranteed.


Although The European Annals of Allergy and Clinical Immunology publishes articles under an open access model, for the time being it does not impose any fees or Author Publication Charges (APC).

There are no submission charges, no charges for rejected/accepted articles, no revision charges, no charges based on the length of a manuscript or type of a manuscript, no supplement charges for the presence of figures/tables or supplementary files, and no fees to publication. The process, from submission to publication, is entirely free.


If a study has been financed by pharmaceutical companies, the Ethics standards of the Journal, the Author Guidelines and the good publication practice (https://www.ismpp.org/gpp3) must be followed (read also the updating https://www.ismpp.org/gpp-2022).

Edra, along with AAIITO and SPAIC, can refuse to accept sponsorship from any commercial enterprise. Advertised articles undergo to the same treatment of non-sponsored articles, being processed with peer-review activity and Sponsors or Clients don’t have control over the editorial decision.

We invite authors or companies which are interested in reprint articles to visit https://www.eurannallergyimm.com/order-offprints/.

Sponsorship for the Journal

The European Annals of Allergy and Clinical Immunology does not receive any external funding for its maintenance and development. All the expenses for maintenance and development of the Journal are covered by the Associazione Allergologi Immunologi Italiani Territoriali e Ospedalieri – AAIITO.


If the authors wish to ask the Editor or Editorial Board to reconsider a rejection of a manuscript, they are allowed to do so. They have to contact the Editorial Office providing a formal letter of appeal, which will be forwarded to the Editor in Chief or a Deputy Editor. Only one appeal is permitted for each manuscript.

The authors can appeal in the case they can demonstrate the existence of an error which took place during revision process or if some fundamental additional data can be provided.


We invite you to read https://www.eurannallergyimm.com/privacy/ for further information about privacy policies.


If you subscribe to our newsletter, you receive a notification email when a ordinary/special issue is published. Every newsletter contains an unsubscribe link in its footer.


The Journal offers to publish correction just in case the errors could affect the interpretation of the study.


Authors are required to perform plagiarism screening, using tools such as CrossCheck by iThenticate or similar, before submission.

Website: www.edraspa.it

European Annals of Allergy and Clinical Immunology ISSN 1764-1489 | © 2024